Recombinant Mouse IL-1ra/IL-1F3

Catalog Number: 480-RM/CF

DESCRIPTION

Source	*E. coli*-derived mouse IL-1ra/IL-1F3 protein Arg8-Gln159, with an N-terminal Met Accession # Q542W1
N-terminal Sequence Analysis	Met
Predicted Molecular Mass	17 kDa

SPECIFICATIONS

Activity	Measured by its ability to inhibit IL-1α-dependent proliferation in D10.G4.1 mouse helper T cells. Symons, J.A. *et al.* (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. *et al.* (eds): IRL Press. 272. The ED_{50} for this effect is 15-60 ng/mL in the presence of 50 pg/mL of Recombinant Human IL-1α/IL-1F1 (Catalog # 200-LA).
Endotoxin Level	<1.0 EU per 1 µg of the protein by the LAL method.
Purity	>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Lyophilized from a 0.2 µm filtered solution in Citric Acid, NaCl and EDTA. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 µg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	• 12 months from date of receipt, ≤ -20 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

BACKGROUND

IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally-occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1β and 19% homology to IL-1α. It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells. In mouse, IL-1 RII does not bind IL-1ra. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both *in vitro* and *in vivo*. Currently, pre-clinical and clinical studies are underway to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.

bio-techne®
Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956
USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373
Europe | Middle East | Africa TEL +44 (0)1235 529449